1.1 billion US dollars: Regeneron buys cancer drug from Sanofi
- Daiichi Sankyo/AstraZeneca’s Enhertu Shows Positive Results in Phase III DESTINY-Breast06 Clinical Trial
- Mn007 Molecules Offer Potential for Combating Streptococcus pyogenes Infection
- Popular Indian Spices Banned in Hong Kong Over Carcinogen Concerns
- AstraZeneca Admits for the First Time that its COVID Vaccine Has Blood Clot Side Effects
- Gut Bacteria Enzymes Offer Hope for ABO Universal Blood Transfusions
- Well-Known Japanese Medicine Exposed for 30 Years of Data Falsification
1.1 billion US dollars: Regeneron buys cancer drug from Sanofi
- AstraZeneca Admits for the First Time that its COVID Vaccine Has Blood Clot Side Effects
- Was COVID virus leaked from the Chinese WIV lab?
- HIV Cure Research: New Study Links Viral DNA Levels to Spontaneous Control
- FDA has mandated a top-level black box warning for all marketed CAR-T therapies
- Can people with high blood pressure eat peanuts?
- What is the difference between dopamine and dobutamine?
- How long can the patient live after heart stent surgery?
1.1 billion US dollars: Regeneron buys cancer drug from Sanofi.
The transaction amount is as high as 1.1 billion US dollars! Regeneron buys cancer drug from Sanofi.
Recently, Regeneron agreed to purchase the immuno-oncology drug Libtayo (simipritimab) from its partner Sanofi in a transaction amounting to US$1.1 billion.
The transaction is a continuation of the global immuno-oncology licensing and collaboration agreement signed by the two parties in 2015.
Before the transaction, the two parties shared Libtayo’s global sales profits and jointly commercialized Libtayo in the United States, while Sanofi was solely responsible for the commercialization of the rest of the world.
Under the agreement, Sanofi will transfer all rights to Libtayo (including the rights to develop, commercialize and manufacture it worldwide) to Regeneron, which will receive the exclusive worldwide license to Libtayo.
Sanofi will receive an up-front payment of $900 million, followed by milestone payments of $200 million once the drug hits certain regulatory and sales targets. In addition, Sanofi will receive an 11% royalty fee on Libtayo’s net profit from global sales.
Libtayo is a prescription drug used to treat cutaneous squamous cell carcinoma (CSCC), locally advanced basal cell carcinoma (BCC), and non-small cell lung cancer (NSCLC).
According to Regeneron’s previously released financial results for the fourth quarter and full year of 2021, Libtayo has brought the company approximately $306 million in net product sales for the full year of 2021.
1.1 billion US dollars: Regeneron buys cancer drug from Sanofi
(source:internet, reference only)
Disclaimer of medicaltrend.org
Important Note: The information provided is for informational purposes only and should not be considered as medical advice.